Skip to main content

Advertisement

Table 2 AF patients in SR 6 months after cardioversion according to warfarin treatment at study end

From: Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation

Variable No warfarin (n = 13) Warfarin (n = 28) p
Medical history
 Age (years) 59 ± 12 68 ± 9 0.008
 Sex (women/men) 4/9 6/22 0.698
 Body mass index (kg/m2) 25 ± 3 25 ± 2 0.602
 Hypertension 2 (15%) 12 (43%) 0.156
 Coronary heart disease 1 (8%) 5 (18%) 0.645
 Diabetes 1 (8%) 0 0.317
 Chronic obstructive pulmonary disease 0 1 (4%) 1.0
 Current cigarette smoking 3 (23%) 2 (7%) 0.307
 CHA2DS2-VASc score 1.2 ± 1.3 2.1 ± 1.5 0.177
Medication
 Angiotensin receptor blocker/study drug 6 (46%) 12 (43%) 0.843
 Angiotensin-converting enzyme inhibitor 0 0
 Beta-blockers 3 (23%) 11 (39%) 0.481
 Calcium channel blockers 3 (23%) 8 (29%) 1.0
 Diuretics 0 2 (7%) 1.0
 Statins 1 (8%) 9 (32%) 0.129
 Antiplatelet therapy 2 (15%) 0 0.095
Blood pressure and heart rate
 Systolic blood pressure (mmHg) 129 ± 18 140 ± 17 0.060
 Diastolic blood pressure (mmHg) 78 ± 6 80 ± 7 0.401
 Ventricular heart rate (beats per minute) 59 ± 7 58 ± 14 0.857
  1. Clinical characteristics of atrial fibrillation patients maintaining sinus rhythm for 6 months after electrical cardioversion with (n = 28) and without (n = 13) warfarin treatment. Values presented as mean ± standard deviation or number (%). Abbreviations: AF Atrial fibrillation; CHA2DS2-VASc score, a measure of stroke risk in patients with atrial fibrillation, with scores ranging from 0 to 9 and higher scores indicating greater risk, n Number of patients, SR Sinus rhythm